Return to content in this issue

 

Desensitization Protocol to Atezolizumab and Bevacizumab after Severe Anaphylaxis in the Treatment of Lung Adenocarcinoma

Gonzalez-Diaz SN1, Villarreal-Gonzalez RV1, De Lira-Quezada CE1, Rocha-Silva GK1, Oyervides-Juarez VM2, Vidal-Gutierrez O2

1Regional Center of Allergy and Clinical Immunology, University Hospital Dr. Jose Eleuterio Gonzalez, Faculty of Medicine, Autonomous University of Nuevo León, Monterrey, Mexico
2Oncology Department, University Hospital Dr. Jose Eleuterio Gonzalez, Faculty of Medicine, Autonomous University of Nuevo León, Monterrey, Mexico

J Investig Allergol Clin Immunol 2021; Vol. 31(3)
doi: 10.18176/jiaci.0637

Key words: Adenocarcinoma, Anaphylaxis, Atezolizumab, Bevacizumab, Desensitization